Clarivate Plc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
7.6%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
$0.71next fiscal year
Monitoring Framework
Key Performance Indicators
Organic Annualized Contract Value (ACV) Growth Quarterly160.0%Target: 2.0% - 3.0%
Recurring Revenue Mix Quarterly
Adjusted EBITDA Margin Quarterly4,120.0%
Free Cash Flow (Full Year) Annually78.9MTarget: $365,000,000 - $435,000,000
Watch Items
- Divestiture of the Life Sciences & Healthcare (LS&H) SegmentTrigger: Execution of a definitive sale agreement for the Life Sciences and Healthcare (LS&H) segmentAction: Re-evaluate full-year 2026 guidance and calculate the net leverage reduction impact on the $4.34B debt load.
- Net Leverage Ratio Deleveraging Progress
- Generative AI Product Adoption and Disintermediation RiskTrigger: Decline in core subscription renewal rates or ACV growth below 1.5%Action: Review customer feedback on newly launched AI tools like the Web of Science Research Assistant and Cortellis AI Assistant.
Research as of 20 Jun 2026